Envision hatte einen Nettoverlust aus nicht fortgeführten Aktivitäten in Höhe von 478,2 Millionen US-Dollar oder 4,10 US-Dollar je Aktie, aufgrund einer Belastung, die eine geschätzte Steuerschuld gegenüber der geplanten Veräußerung des Segmentes Medizinische Transporte widerspiegelt, was zu einem Nettoverlust führt, der den Gesellschaftern von Envision von $ 447,5 zuzurechnen ist Millionen oder 3,84 US-Dollar je Aktie;
NASHVILLE, Tenn. & GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--Envision Healthcare Corporation (“Envision”) (NYSE: EVHC) today reported financial results for the three months ended March 31, 2017. These results reflect the reporting of Envision’s Medical Transportation segment as discontinued operations for the period, after the Board of Directors approved a plan to market that business, and eventually divest it, to prospective buyers.
Highlights for the First Quarter of 2017 include:
Net revenue of $1.88 billion from continuing operations and $593.5 million from discontinued operations;
Net earnings from continuing operations were $30.7 million, or $0.26 per diluted share. Envision had a net loss from discontinued operations of $478.2 million, or $4.10 per share, due to a charge that reflects an estimated tax liability due upon the planned divestiture of its Medical Transportation segment, resulting in a net loss attributable to Envision common stockholders of $447.5 million, or $3.84 per share;
Adjusted net earnings of $94.4 million consisting of $80.4 million from continuing operations and $14.0 million from discontinued operations;
Adjusted net earnings of $0.77 per share, which includes $0.66 per diluted share from continuing operations and $0.11 per diluted share from discontinued operations; and
Adjusted EBITDA of $282.6 million, consisting of $210.3 million from continuing operations and $72.3 million from discontinued operations.
During the first quarter of 2017, Envision reached a settlement to retroactively terminate its largest population health management services contract, offered through its Evolution Health subsidiary, resulting in a loss of $7.1 million, which is included in net gain on disposals and deconsolidations.